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INTRODUCTION {#jmv24249-sec-0002}
============

Human metapneumovirus (hMPV) is a new respiratory viral pathogen identified in the Netherlands in 2001 \[van den Hoogen et al., [2001](#jmv24249-bib-0018){ref-type="ref"}\]. hMPV is an RNA virus with a negative‐sense, single‐stranded, non‐segmental genome. hMPV belongs to the *Metapneumovirus* genus within the *Pneumovirinae* subfamily of the *Paramyxoviridae* family and is currently the only member of the genus *Metapneumovirus* that is known to cause disease in humans.

hMPV is widespread throughout the world \[Feuillet et al., [2012](#jmv24249-bib-0008){ref-type="ref"}\] and infects human populations of different age groups, especially children younger than 5 years of age \[McAdam et al., [2004](#jmv24249-bib-0014){ref-type="ref"}; Vicente et al., [2006](#jmv24249-bib-0021){ref-type="ref"}; Matsuzaki et al., 2008; Zhu et al., [2011](#jmv24249-bib-0026){ref-type="ref"}; Zhang,,[2012](#jmv24249-bib-0025){ref-type="ref"}t al., 2012; Lu et al., [2013](#jmv24249-bib-0013){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}; Xiao et al., [2013](#jmv24249-bib-0023){ref-type="ref"}\]. hMPV causes acute upper and lower respiratory tract infections. The clinical manifestations of hMPV infection are similar to those of respiratory syncytial virus infection \[van den Hoogen et al., [2003](#jmv24249-bib-0019){ref-type="ref"}; van den Hoogen et al., [2004](#jmv24249-bib-0020){ref-type="ref"}\].

Based on the coding genes, hMPV has been classified into genotypes A and B, which are divided into 4 sub‐genotypes: A1, A2, B1, and B2. The sub‐genotype A2 is divided further into sub‐genotypes A2a and A2b. The new sub‐genotype A2b was discovered in children with respiratory tract infections by German researchers in 2006 \[Huck et al., [2006](#jmv24249-bib-0011){ref-type="ref"}\]. The previous studies have identified distinct predominant prevalences of hMPV genotypes in different regions and different years \[Matsuzaki et al., 2008; Pitoiset et al., [2010](#jmv24249-bib-0016){ref-type="ref"}; Apostoli et al., [2012](#jmv24249-bib-0002){ref-type="ref"}; Kim et al., [2012](#jmv24249-bib-0012){ref-type="ref"}; Lu et al., [2013](#jmv24249-bib-0013){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}\]. However, the data on the epidemiological and clinical characteristics of various genotypes of hMPV are currently limited.

Xiao et al in our research group has reported that hMPV is an important pathogen causing acute lower respiratory tract infections in children of the Hunan Province \[Xiao et al., [2013](#jmv24249-bib-0023){ref-type="ref"}\]. To further explore the epidemiological and clinical features of various genotypes of hMPV, we summarized the data on the hMPV positive patients hospitalized for acute lower respiratory tract infections in Hunan Province over a period of 3.5 years (Sep. 2007--Feb. 2011)

MATERIALS AND METHODS {#jmv24249-sec-0003}
=====================

Patients and Specimens {#jmv24249-sec-0004}
----------------------

Nasopharyngeal aspirates samples were collected from 2613 children hospitalized for acute lower respiratory tract infection at Hunan provincial People\'s Hospital, China, during fixed 2 days of each week between September 2007 and February 2011. All enrolled hospitalized patients were 14 years of age or younger and were admitted for acute lower respiratory tract infection (pneumonia, bronchitis, bronchiolitis, and asthma complicate pulmonary infection). Acute lower respiratory tract infection was diagnosed on the basis of clinical and radiologic findings. The enrolled children were consulting with an illness where an acute or worsened cough was the main or dominant symptom, or had a clinical presentation that suggested a lower respiratory tract infection, with a duration of ≤ 28 days. All nasopharyngeal aspirates were collected within 1--3 days of admission. Demographic data and details of the clinical findings were recorded from case history. Informed consent was obtained from the parents of all children who provided specimens. The study protocol was approved by the hospital ethics committee.

Collection and Processing of Nasopharyngeal Aspirates Samples {#jmv24249-sec-0005}
-------------------------------------------------------------

All nasopharyngeal aspirates were collected and transported immediately to the laboratory at the National Institute for Viral Disease Control and Prevention, China CDC, and stored at --80°C until required for further analysis. Viral DNA and RNA were extracted from 140 µl of each nasopharyngeal aspirates specimen using the QIAamp viral DNA and the QIAamp viral RNA Mini Kits (Qiagen, Shanghai, China) according to the manufacturer\'s instructions. cDNA was synthesized using random hexamer primers with the Superscript II RH^--^ reverse transcriptase (Invitrogen, Carlsbad, CA).

Detection of hMPV {#jmv24249-sec-0006}
-----------------

Screening for hMPV was conducted using traditional PCR methods. hMPV forward (5′‐CCC TTT GTT TCA GGC CAA‐3′) and reverse (5′‐GCA GCT TCA ACA GTA GCT G‐3′) primers, which target the M gene and generate a 416‐bp product, were used as described previously \[Bellau‐Pujol et al., [2005](#jmv24249-bib-0003){ref-type="ref"}\]. All PCR products were purified using the QIAquick PCR purification kit (Qiagen). The reaction mix contained 10 pmol of each primer and 1.25 units of EXTaq DNA polymerase (Takara Bio Inc., Tokyo, Japan). Reactions were incubated at 94°C for 8 min, followed by 35 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 45 s, followed by a final extension at 72°C for 10 min.

Nucleotide Sequence Analysis {#jmv24249-sec-0007}
----------------------------

All PCR products were purified using the QIAquick PCR purification kit (Qiagen) and cloned into the pGEM‐T Easy Vector (Promega, Madison, WI) and then sequenced. Sequences were determined and analyzed using the DNASTAR software package. Phylogeneticanalysis was performed with Mega version 5.2 by using 1,000 bootstrapped replicates and the neighborjoining algorithm. The GenBank accession numbers of the previously published sequences are as follows: CAN98‐74(AY145258), CAN98‐75(AY145259), CAN99‐81(AY145264), CAN97‐82(AY145265), CAN00‐12(AY145267), CAN00‐14(AY145269), CAN00‐16(AY145271), BJ1887(DQ843659) and JPS03‐240(AY530095).

Screening for Other Respiratory Viruses {#jmv24249-sec-0008}
---------------------------------------

A standard reverse transcription‐PCR technique was used to screen for respiratory syncytial virus (RSV), human rhinovirus (HRV), influenza viruses (IFVA, IFVB), parainfluenza viruses (PIV types 1--3), human coronaviruses HKU1 (HCoV‐HKU1), and NL63 (HCoV‐NL63), and PCR for adenovirus (ADV) and human bocavirus (HBOV) \[Hierholzer et al., [1993](#jmv24249-bib-0010){ref-type="ref"}; Bellau‐Pujol et al., [2005](#jmv24249-bib-0003){ref-type="ref"}\].

Statistical Analysis {#jmv24249-sec-0009}
--------------------

Inferential statistics performed included non‐parametric Mann‐Whitney U test for continuous variables, with data reported as medians and 25th and 75th interquartile ranges (IQR). Categorical variables were compared using the chi‐square test or Fisher\'s exact test. Multivariate logistic regression analysis was used to identify independent risk factors. Variables with a plausible relationship with P values less than 0.2 in the univariate analysis were entered into the multivariate analyses. Results are summarized as odds ratios (OR) and 95% confidence intervals (CI). All analyses were performed using SPSS version 20.0 software (SPSS Inc., Chicago, IL). *P *\< 0.05 was considered statistically significant.

RESULTS {#jmv24249-sec-0010}
=======

Patient Characteristics {#jmv24249-sec-0011}
-----------------------

In total, 2613 patients were included, and about 100 cases were excluded for samples missing when those were transporting from Changsha to Beijing (March--June 2009). The enrolled 2613 study samples represented 23.03% of 11348 admissions for acute lower respiratory tract infection to Hunan provincial People\'s Hospital, China. The ages of enrolled children ranged from 1 day to 166 months, with a median age of 11 (IQR 5--24) months. The majority of the specimens (2231/2613, 85.4%) were collected from patients under 36 months old (Figure [1](#jmv24249-fig-0001){ref-type="fig"}), and the male to female ratio was 1.86:1 (1698:915).

![Age distribution of hMPV in children with acute lower respiratory tract infections during 3.5‐years study period.](JMV-87-1839-g001){#jmv24249-fig-0001}

Detection of hMPV and Other Viral Agents {#jmv24249-sec-0012}
----------------------------------------

Of 2613 respiratory specimens tested in the study period, at least one respiratory virus was detected in 1629 (62.34%). The most commonly detected virus was RSV (503, 19.25%), followed by HRV (475, 18.18%), PIV‐3 (317, 12.13%), HBOV (224, 8.57%), ADV (153, 5.86%), hMPV (135, 5.2%), IFVB (62, 2.37%), IFVA (51, 1.95%), HCoV‐HKU1 (20, 0.77%), PIV‐1 (15, 0.57%), PIV‐2 (11, 0.42%), HCoV‐NL63 (11, 0.42%). Sixty‐two of 135 (45.9%) hMPV‐positive samples were found to be coinfected with other respiratory viruses, including twenty‐two with HBOV, seventeen with RSV, fifteen with HRV, thirteen with PIV3, six with ADV, three with IFVB, two with PIV4, two with HCoV‐HKU1, and one with HCoV‐NL63. HBOV was the most common coinfecting virus, accounting for 22/62 (35.5%) coinfections. Among the patients with co‐detections, 36.3% (49/135) were positive for hMPV plus one additional viral agent and 9.6% (13/135) were positive for hMPV plus two or three additional viruses; of these 9.6%, seven patients were positive for three and six patients were positive for four viral agents. The epidemiological and clinical characteristics of patients infected with hMPV single infection and patients with hMPV co‐detections were similar. However, rhonchus were more common in patients with hMPV co‐detections (χ^2^ = 8.427, *P* = 0.004) (Table [I](#jmv24249-tbl-0001){ref-type="table"}). The univariates of cyanosis, crackles, and rhonchus were entered into the multivariate analyses, and rhonchus was associated with hMPV co‐infection (OR = 3.057; 95%CI 1.463--6.385; *P* = 0.003).

###### 

Clinical Characteristics of Patients Infected With Human Metapneumovirus (hmpv) From September 2007 Through August 2008

                                                                      hMPV‐A (n = 98)   hMPV‐B (n = 37)   *P*‐value                                        single hMPV‐A (n = 51)   single hMPV‐B (n = 22)   *P*‐value                                        single infection hMPV (n = 73)   co‐infection hMPV (n = 62)   *P*‐value
  ------------------------------------------------------------------- ----------------- ----------------- ------------------------------------------------ ------------------------ ------------------------ ------------------------------------------------ -------------------------------- ---------------------------- ------------------------------------------------
  Male gender                                                         75(76.5)          28(75.7)          0.917                                            39(76.5)                 18(81.8)                 0.762[^a^](#jmv24249-note-0001){ref-type="fn"}   57(78.1)                         46(74.2)                     0.596
  Age, months, median(IQR)[^b^](#jmv24249-note-0002){ref-type="fn"}   10 (6--23.25)     10 (5.5--15.5)    0.501                                            11 (6--24)               7.5 (5.0--11.25)         0.098                                            10 (6--20)                       8 (5--16)                    0.599
  Age in months                                                                                           0.598                                                                                              0.349[^a^](#jmv24249-note-0001){ref-type="fn"}                                                                 0.958
  ≤6                                                                  32(32.7)          12(32.4)                                                           16(31.4)                 8(36.4)                                                                   24(32.9)                         20(32.3)                     
  6.1 to≤12                                                           33(33.7)          15(40.5)                                                           15(29.4)                 10(45.5)                                                                  25(34.2)                         23(37.1)                     
  12.1 to≤36                                                          24(24.5)          9(24.3)                                                            16(31.4)                 3(13.6)                                                                   19(26.0)                         14(22.6)                     
  \>36                                                                9(9.2)            1(2.7)                                                             4(7.8)                   1(4.5)                                                                    5(6.8)                           5(8.1)                       
  LOS, days, median (IQR)[^b^](#jmv24249-note-0002){ref-type="fn"}    7 (6--10)         8 (7--9)          0.322                                            7 (6--9)                 8 (6.75--9)              0.296                                            7 (6--9)                         8 (6--10)                    0.326
  Symptoms and signs                                                                                                                                                                                                                                                                                                        
  Fever                                                               50(51.0)          20(54.1)          0.753                                            31(60.8)                 9(40.9)                  0.084                                            40(54.8)                         30(48.4)                     0.458
  Cough^2^                                                            95(96.9)          36(97.3)          1                                                49(96.1)                 21(95.5)                 1                                                70(95.9)                         61(98.4)                     0.624[^a^](#jmv24249-note-0001){ref-type="fn"}
  Wheezing                                                            54(55.1)          25(67.6)          0.190                                            28(54.9)                 16(72.7)                 0.153                                            44(60.3)                         35(56.5)                     0.653
  Shortness of breath                                                 11(11.2)          5(13.5)           0.767[^a^](#jmv24249-note-0001){ref-type="fn"}   7(13.7)                  4(18.2)                  0.724[^a^](#jmv24249-note-0001){ref-type="fn"}   11(15.1)                         5(8.1)                       0.210
  Cyanosis                                                            2(2.0)            3(8.1)            0.126[^a^](#jmv24249-note-0001){ref-type="fn"}   2(3.9)                   3(13.6)                  0.157[^a^](#jmv24249-note-0001){ref-type="fn"}   5(6.8)                           0                            0.062[^a^](#jmv24249-note-0001){ref-type="fn"}
  Crackles                                                            70(71.4)          29(78.4)          0.415                                            39(76.5)                 18(81.8)                 0.762[^a^](#jmv24249-note-0001){ref-type="fn"}   57(78.1)                         42(67.7)                     0.176
  Rhonchus                                                            45(45.9)          11(29.7)          0.089                                            19(37.3)                 3(13.6)                  0.044                                            22(30.1)                         34(54.8)                     0.004
  Diarrhea^2^                                                         10(10.2)          9(24.3)           0.035                                            6(11.8)                  5(22.7)                  0.289[^a^](#jmv24249-note-0001){ref-type="fn"}   11(15.1)                         8(12.9)                      0.718
  supplemental oxygen                                                 8(8.2)            7(18.9)           0.120[^a^](#jmv24249-note-0001){ref-type="fn"}   4(7.8)                   3(13.6)                  0.424                                            7(9.6)                           8(12.9)                      0.541
  Coinfection                                                         47(48.0)          15(40.5)          0.440                                            /                        /                        /                                                /                                /                            /
  Underlying disease                                                  22(22.4)          13(35.1)          0.134                                            11(21.6)                 5(22.7)                  1                                                16(21.9)                         19(30.6)                     0.249
  Seasonal distribute                                                                                     0.366[^a^](#jmv24249-note-0001){ref-type="fn"}                                                     0.570[^a^](#jmv24249-note-0001){ref-type="fn"}                                                                 0.368
  Spring                                                              49(50.0)          16(43.2)                                                           30(58.8)                 10(45.5)                                                                  40(54.8)                         25(40.3)                     
  Summer                                                              8(8.2)            6(16.2)                                                            3(5.9)                   3(13.6)                                                                   6(8.2)                           8(12.9)                      
  Autumn                                                              8(8.2)            5(13.5)                                                            5(9.8)                   2(9.1)                                                                    7(9.6)                           6(9.7)                       
  Winter                                                              33(33.7)          10(27.0)                                                           13(25.5)                 7(31.8)                                                                   20(27.4)                         23(37.1)                     

Fisher\'s exact test,

Mann‐Whitney U test, all the other: Chi‐square test.

hMPV‐A indicate type A hMPV, hMPV‐B indicate type B hMPV, single hMPV‐A indicate single type A hMPV infection, single hMPV‐B indicate single type B hMPV infection.

Seasonal distribution: Spring (March‐May), Summer (June‐August), Autumn (September‐ November), Winter (December‐February).

IQR, interquartile range; LOS, length of hospital stay.

© 2015 Wiley Periodicals, Inc.
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Epidemiology of hMPV {#jmv24249-sec-0013}
--------------------

Approximately 6.1% (103/1698) of the males and 3.5% (32/915) of the females tested positive for hMPV in this study. The male‐to‐female ratio in the hMPV‐infected group was 3.2:1 and differed significantly between the patients with and without hMPV infections (χ^2^ = 8.007, *P* = 0.005). The age of patients infected with hMPV varied from 20 days to 12 years of age (median (IQR), 10 (6--16) months), and 68.1% (92/135) were ≤ 12 months of age. Children 7--12 months of age exhibited the highest infection rate (7.2%). The hMPV infection rates among four age groups differed significantly (χ^2^ = 12.808, *P *= 0.005; Fig. [1](#jmv24249-fig-0001){ref-type="fig"}). hMPV infections occurred most frequently in spring. The positive rate of hMPV in spring reached 10.7% (65/607). The seasonal distribution exhibited statistically significant differences in the positive rates of hMPV among four different seasons (χ^2^ = 57.483, *P *= 0.000; Fig. [2](#jmv24249-fig-0002){ref-type="fig"}).

![Seasonal distribution of hMPV infections in children with acute lower respiratory tract infections, September 2007--February 2011.](JMV-87-1839-g002){#jmv24249-fig-0002}

Clinical Characteristics of hMPV in Children {#jmv24249-sec-0014}
--------------------------------------------

Among the 135 pediatric patients with acute lower respiratory tract infections who tested positive for hMPV, the majority had developed a cough (131 patients, 97.0%), 70 experienced a fever (51.9%), 79 suffered from wheezing (58.5%), 99 (73.3%) developed moist rales, and rhonchi were audible in 56 patients (41.5%). In addition, 16 patients experienced shortness of breath (11.9%), 5 developed cyanosis (3.7%), 19 had diarrhea (14.1%), and 15 required supplemental oxygen (11.1%). Thirty‐five patients developed underlying disorders or complications (25.9%), including 6 patients had thrush, 6 patients had granulocytopenia, 3 children had congenital heart defects, 3 children had cytomegao‐ virus infection, and some other diseases or complications. All hospitalized patients exhibited good prognoses and the median length of hospital stay was 7 (IQR 6--9) days.

Phylogenetic Analysis of hMPV {#jmv24249-sec-0015}
-----------------------------

The sequence of positive products and standard sequences from GenBank exhibited high homology (96%--100%). Phylogenetic analyses indicated that the 135 hMPV specimens were classified into the two main genetic lineages, A and B. Ninety‐eight (98/135, 72.6%) hMPV strains were subgroup A2b, thirty‐six (26.6%) strains were subgroup B1, one was subgroup B2, and none were either subgroup A1 and A2a. The nucleotide and deduced amino acid sequences of the M gene of 135 hMPV specimens were compared with those of hMPV strains available at the GenBank site (Fig. [3](#jmv24249-fig-0003){ref-type="fig"}).

![Phylogenetic analysis of nucleotide sequences from the partial M gene of the 135 hMPV strains from nasopharyngeal aspirates. Phylogenetic trees were constructed by the neighbor‐joining method using MEGA5.2. The viral sequences in black solid rhombus were generated from GenBank (GenBank accession no. CAN98‐74 (AY145258), CAN98‐75 (AY145259), CAN99‐81 (AY145264), CAN97‐82 (AY145265), CAN00‐ 12 (AY145267), CAN00‐14 (AY145269), CAN00‐16 (AY145271), BJ1887 (DQ843659) and JPS03‐240 (AY530095)); other reference sequences were obtained from the present study. Genotypes of the previously published hMPV sequences: CAN00‐12 and CAN00‐16 were subgroup A2a; BJ1887 and JPS03‐ 240 were subgroup A2b; CAN00‐14 and CAN99‐81 were subgroup A1; CAN97‐82 was subgroup B1; CAN98‐ 74 and CAN98‐75 were subgroup B2.](JMV-87-1839-g003){#jmv24249-fig-0003}

Epidemiological and Clinical Characteristics of hMPV Genotypes A and B {#jmv24249-sec-0016}
----------------------------------------------------------------------

The epidemiological and clinical data of 135 pediatric patients infected with type A (98 cases) or type B hMPV (37 cases) were summarized and analyzed. The results of the distribution of epidemic seasons indicated that hMPV genotypes A and B prevailed alternately in different years. From the autumn of 2007 to the summer of 2008, hMPV genotype A2b was the predominant epidemic strain. From the autumn of 2008 to the winter of 2009, the predominant genotype of hMPV changed to combined A2b and B1 genotype. From the spring to the winter of 2010, hMPV genotype B1 became the predominant epidemic strain (Fig. [4](#jmv24249-fig-0004){ref-type="fig"}). Comparison studies revealed that the epidemiological data and clinical characteristics were largely similar between the patients infected with genotype A hMPV and patients infected with genotype B hMPV. However, patients infected with genotype B hMPV developed diarrhea more frequently compared with pediatric patients infected with genotype A hMPV (*χ^2^ = *4.328, *P *= 0.035). Excluding the factor of mixed infection, the epidemiological and clinical characteristics of patients infected with type A hMPV alone and patients infected with type B hMPV alone were also basically similar. However, rhonchus were more common in patients with type A hMPV infection (*χ^2^ = *4.072, *P *= 0.044). The univariates of fever, wheezing, cyanosis, rhonchus were entered into the multivariate analyses, and rhonchus was associated with type A hMPV infection (OR = 0.164; 95%CI 0.036--0.751; *P *= 0.020).

![Seasonal distribution of hMPV genetypes from September 2007 to February 2011.](JMV-87-1839-g004){#jmv24249-fig-0004}

DISCUSSION {#jmv24249-sec-0017}
==========

The present study summarized the prevalence and clinical features of hMPV infections in Hunan Province between September 2007 and February 2011, including the 76 hMPV cases (Sep. 2007--Aug. 2008) reported in the preliminary study \[Xiao et al., [2013](#jmv24249-bib-0023){ref-type="ref"}\]. The present study revealed that the hMPV positive rate was 5.2%, in hospitalized children with acute lower respiratory tract infections in Hunan Province, that was similar to Beijing \[Zhu et al., [2011](#jmv24249-bib-0026){ref-type="ref"}; Lu et al., [2013](#jmv24249-bib-0013){ref-type="ref"}\], higher than Southern China (2.6%) \[Cai et al., [2014](#jmv24249-bib-0005){ref-type="ref"}\], and lower than Chongqing (10.2%) \[Zhang et al., [2012](#jmv24249-bib-0025){ref-type="ref"}\] and Taiwan (23%) \[Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}\]. Compared with studies in other countries, that was higher than the reported rate in Japan (2.5%) \[Matsuzaki et al., 2008\], lower than the reported rate in Germany (11.9%) \[Reiche et al., [2014](#jmv24249-bib-0017){ref-type="ref"}\], and similar to the reported rates in the United States \[van den Hoogen et al., [2003](#jmv24249-bib-0019){ref-type="ref"}; Edwards et al., [2013](#jmv24249-bib-0006){ref-type="ref"}\] and South Korea \[Kim et al., [2012](#jmv24249-bib-0012){ref-type="ref"}\] (6% and 7.1%, respectively). The variation in hMPV detection rates between various regions may be related to the differences in climate, geographic locations, year and human populations.

The present study found that the hMPV positive rate was higher in male pediatric patients, which is consistent with the most of the previous studies \[Peiris et al., [2003](#jmv24249-bib-0015){ref-type="ref"}; van den Hoogen et al., [2003](#jmv24249-bib-0019){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}\], but different from a study in the United States which found hMPV infections were equally distributed between males and females \[McAdam et al., [2004](#jmv24249-bib-0014){ref-type="ref"}\]. Furthermore most previous studies have indicated that the majority of hMPV‐positive patients are children of young ages \[McAdam et al., [2004](#jmv24249-bib-0014){ref-type="ref"}; Vicente et al., [2006](#jmv24249-bib-0021){ref-type="ref"}; Lu et al., [2013](#jmv24249-bib-0013){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}; Reiche et al., [2014](#jmv24249-bib-0017){ref-type="ref"}\], which is similar to the findings of the present study. The peak of hMPV infections was found in the spring in the present study, which is similar to that of Beijing \[Zhu et al., [2011](#jmv24249-bib-0026){ref-type="ref"}\], but different from that of Chongqing where the peak of hMPV epidemics are observed in the spring/summer and the winter/spring seasons \[Zhang et al., [2012](#jmv24249-bib-0025){ref-type="ref"}\]. In the United States, hMPV infections have been reported to occur predominately in the winter and spring seasons \[McAdam et al., [2004](#jmv24249-bib-0014){ref-type="ref"}\]. These unique characteristics of hMPV infections may be related to the geographic region and climate, and requires the further study for verification.

In the present study the most common clinical symptoms of hMPV‐positive patients included coughing, wheezing and fever, which in some pediatric patients, were accompanied by shortness of breath, cyanosis and moist rales heard in pulmonary auscultation, whcih were similar to those reported previously \[Zhang et al., [2012](#jmv24249-bib-0025){ref-type="ref"}; Lu et al., [2013](#jmv24249-bib-0013){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}\]. The present study revealed a rather high mixed infection of hMPV with other viruses (45.9%) and HBOV was the most frequently detected virus with hMPV. The rates of hMPV coinfection of previous studies range from approximately 9.4% to 70.8% \[Zhu et al., [2011](#jmv24249-bib-0026){ref-type="ref"}; Fathima et al., [2012](#jmv24249-bib-0007){ref-type="ref"}; Kim et al., [2012](#jmv24249-bib-0012){ref-type="ref"}; Zhang et al., [2012](#jmv24249-bib-0025){ref-type="ref"}; Lu et al., [2013](#jmv24249-bib-0013){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}; Cai et al., [2014](#jmv24249-bib-0005){ref-type="ref"}\], and the commonly co‐detected viruses include RSV, HRV and PIV‐3. These discrepancies are most likely due to the differences in the types of viruses examined and the test methods employed in the studies. However, the discrepancies may also be related to the selection of research objects, geographic regions and research periods. Previous studies have indicated that mixed infection may aggravate the diseases and affect prognosis \[Greensill et al., [2003](#jmv24249-bib-0009){ref-type="ref"}\]. In the present study, lung auscultation did reveal that rhonchi were more common in patients with mixed hMPV infection compared with patients with single hMPV infection. However, no other significant differences were found between the patients, including the requirement of supplemental oxygen and duration of hospitalization.

Consistent with the findings reported by Xiao et al \[[2013](#jmv24249-bib-0023){ref-type="ref"}\], the present study revealed that both hMPV genotype A and genotype B were prevalent in the Changsha area from September 2007 to February 2011. hMPV genotypes A2 and B1 were the most predominant genotypes. The annual distribution indicated that genotype A2 and genotype B1 prevailed alternately. Previous studies have reported the prevalence of certain predominant hMPV genotypes in a given year. hMPV sub‐genotypes may vary in different years and alternative predominance of hMPV sub‐genotypes has been observed \[Matsuzaki et al., 2008; Pitoiset et al., [2010](#jmv24249-bib-0016){ref-type="ref"}; Kim et al., [2012](#jmv24249-bib-0012){ref-type="ref"}; Lu et al., [2013](#jmv24249-bib-0013){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}\]. The present study found that the epidemiological characteristics and clinical features were fundamentally similar among patients infected with different genotypes of hMPV, which is consistent with the results of some studies \[Bosis et al., [2008](#jmv24249-bib-0004){ref-type="ref"}; Wei et al., [2013](#jmv24249-bib-0022){ref-type="ref"}\]. Diarrhea was a clinical manifestation that occurred more frequently in patients infected with type B hMPV compared with patients infected with type A hMPV in this study. However, there are different epidemiological and clinical findings in other two studies \[Matsuzaki et al., 2008; Kim et al., [2012](#jmv24249-bib-0012){ref-type="ref"}\]. Furthermore, a study indicated that patients with type A hMPV infection are often associated with more severe symptoms \[Vicente et al., [2006](#jmv24249-bib-0021){ref-type="ref"}\]. However, there is no apparent link between the genotype of hMPV and the severity factors of the disease in other studies \[Agapov et al., [2006](#jmv24249-bib-0001){ref-type="ref"}; Pitoiset et al., [2010](#jmv24249-bib-0016){ref-type="ref"}\]. Certainly, more data are needed to elucidate this issue.

In conclusion, the present study explores the epidemiological and clinical manifestations of infections with various genotypes of hMPV and especially the predominant prevalence of hMPV genotypes in different years. However, retrospective analysis was conducted in the present study without control samples, and the sample sizes of certain sub‐genotypes of hMPV were small. These are the major limitations. And a long period of data accumulation with a larger sample size and control is required in the future study.
